Skip to main content
Fig. 3 | Cell & Bioscience

Fig. 3

From: Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants

Fig. 3

R3P1-E4 suppresses SARS-CoV-2 infection in vivo. A–C The in vivo antiviral effect of R3P1-E4 against SARS-CoV-2. 8-month-old male mice were administrated intraperitoneally with R3P1-E4 Ab (25 mg/kg) (n = 5) or IgG control (n = 5) 24 h before and 24, 48 and 72 h after intranasal challenge with the SARS-CoV-2 mouse adapted strain MASCp36 (30 PFU/mouse) (A). Lung and trachea viral loads were tested by qRT-PCR (B) and RNA scope (C) at 3 dpi. D The quantification of (C). E The lung damage caused by SARS-CoV-2 infection was examined by H&E staining. Scale bar: 100 μm. F-G The in vivo antiviral effect of R3P1-E4 against SARS-CoV-2. 8-month-old male mice were administrated intraperitoneally with R3P1-E4 Ab (25 mg/kg) (n = 5) or IgG control (n = 5) at 2 h and 24 h after infection with SARS-CoV-2 MASCp36 strain (600 PFU/mouse) (F). The survival of mice was monitored during 14 dpi (G). qRT-PCR data (E) are shown as Means ± SD, ****P < 0.0001 by unpaired Student’s t test

Back to article page